Focus: Sionna Therapeutics is a public biotech company focused on small-molecule therapeutics targeting cystic fibrosis, a rare genetic disease with high unmet medical need. Founded in 2019 and headquartered in Waltham, MA, the company operates as a clinical-stage biotech with a concentrated pipeline.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Sionna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sionna Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sionna Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
OrbiMed fund tied to Sionna (NASDAQ: SION) director trims 55K shares - Stock Titan
OrbiMed fund tied to Sionna (NASDAQ: SION) director trims 55K shares Stock Titan
OrbiMed-backed Sionna (NASDAQ: SION) sees fund share sale - Stock Titan
OrbiMed-backed Sionna (NASDAQ: SION) sees fund share sale Stock Titan
OrbiMed (SION) cuts Sionna stake to 6.6% after April share sales - Stock Titan
OrbiMed (SION) cuts Sionna stake to 6.6% after April share sales Stock Titan
OrbiMed fund linked to Sionna Therapeutics (SION) director sells 510K shares - Stock Titan
OrbiMed fund linked to Sionna Therapeutics (SION) director sells 510K shares Stock Titan
OrbiMed entities sell Sionna Therapeutics (SION) stock under 10b5-1 plan - Stock Titan
OrbiMed entities sell Sionna Therapeutics (SION) stock under 10b5-1 plan Stock Titan
Operating cash flow per share of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Operating cash flow per share of Sionna Therapeutics, Inc. – NASDAQ:SION TradingView
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo